Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CART-ddBCMA |
| Synonyms | |
| Therapy Description |
CART-ddBCMA are autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) with a synthetic antigen-binding domain targeting BCMA (TNFRSF17) and containing CD137 (4-1BB) and CD3 zeta signaling domains, which potentially have antitumor activity (PMID: 35468618). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CART-ddBCMA | Anitocabtagene autoleucel | TNFRSF17 Immune Cell Therapy 27 | CART-ddBCMA are autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) with a synthetic antigen-binding domain targeting BCMA (TNFRSF17) and containing CD137 (4-1BB) and CD3 zeta signaling domains, which potentially have antitumor activity (PMID: 35468618). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06413498 | Phase III | Cyclophosphamide + Fludarabine Carfilzomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide CART-ddBCMA Carfilzomib + Dexamethasone | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3) | Recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 1 |
| NCT05396885 | Phase II | CART-ddBCMA | Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Active, not recruiting | USA | 0 |
| NCT04155749 | Phase I | CART-ddBCMA ACLX-001 | Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT07045909 | Phase II | Cyclophosphamide + Fludarabine Bortezomib + Daratumumab + Dexamethasone + Lenalidomide CART-ddBCMA Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) (GEM-AnitoFIRST) | Recruiting | ESP | 0 |
CKB BOOST